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http:WHAT THIS PAPER ADDS
Abdominal aortic aneurysms generally enlarge and rupture unless resected or repaired. To date, pharmacological
strategy has proven ineffective in preventing disease progression. In this study, rapamycin proved remarkably
effective in preventing progression of established experimental aneurysms. Despite beginning therapy after
aneurysm initiation, rapamycin preserved aortic architecture, and attenuated aortic mural angiogenesis and
macrophage accumulation. This study adds to the growing body of evidence supporting the use of rapamycin for
medical abdominal aortic aneurysm disease management.Objectives: Abdominal aortic aneurysm (AAA) is a chronic inﬂammatory disease affecting 4e8% of men older
than 60 years. No pharmacologic strategies limit disease progression, aneurysm rupture, or aneurysm-related
death. We examined the ability of rapamycin to limit the progression of established experimental AAAs.
Methods: AAAs were created in 10e12-week-old male C57BL/6J mice via the porcine pancreatic elastase (PPE)
infusion method. Beginning 4 days after PPE infusion, mice were treated with rapamycin (5 mg/kg/day) or an
equal volume of vehicle for 10 days. AAA progression was monitored by serial ultrasound examination. Aortae
were harvested for histological analyses at sacriﬁce.
Results: Three days after PPE infusion, prior to vehicle or rapamycin treatment, aneurysms were enlarging at an
equal rate between groups. In the rapamycin group, treatment reduced aortic enlargement by 38%, and 53% at 3
and 10 days, respectively. On histological analysis, medial elastin and smooth muscle cell populations were
relatively preserved in the rapamycin group. Rapamycin treatment also reduced mural macrophage density and
neoangiogenesis.
Conclusion: Rapamycin limits the progression of established experimental aneurysms, increasing the translational
potential of mechanistic target of rapamycin-related AAA inhibition strategies.
 2014 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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Abdominal aortic aneurysm (AAA) is a lethal, age- and
gender-related chronic inﬂammatory disease. Approxi-
mately one million Americans aged 50e84 years1 are at risk
for premature, AAA-related death. Key pathological features
present in AAA disease include mural leukocyte inﬁltration,
neoangiogenesis, smooth muscle cell (SMC) depletion,
extracellular matrix degradation, and progressive intra-
luminal laminar thrombus accumulation.2 Although multiple
pharmacological inhibition strategies have succeeded in
experimental aneurysm models,3e10 none have beenrtin Rouer and Baohui Xu contributed equally.
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//dx.doi.org/10.1016/j.ejvs.2014.02.006successfully translated to clinical practice. Therefore, surgi-
cal repair, limited to patients suffering from advanced dis-
ease, remains the only available option.11e13
Rapamycin is approved by the US Food and Drug
Administration for preventing rejection of transplant allo-
grafts, as well as coronary artery restenosis following
transluminal angioplasty and stenting.14,15 Mechanistically,
rapamycin disrupts cellular signaling through mechanistic/
mammalian target of rapamycin (mTOR), a serine/threonine
kinase modulating numerous biological processes, including
cell growth, metabolism, aging, angiogenesis, and inﬂam-
mation.16 In experimental atherosclerosis, rapamycin
treatment increases plaque stability and limits disease
progression.17e19 Rapamycin is effective in limiting experi-
mental aneurysm progression when administered prior to
AAA initiation.20,21 However, of critical relevance to trans-
lational potential, the ability of rapamycin to limit existing
aneurysm progression has not been examined to date.
In this study, rapamycin therapy was initiated 4 days after
intra-aortic infusion of porcine pancreatic elastase (PPE), at
Figure 1. Effect of rapamycin treatment on body weight. Data on
body weight are presented as the percentage of baseline levels
(prior to vehicle or rapamycin treatment). Two-way analysis of
variance with the Bonerroni correction, p < .01 between two
groups; n ¼ 7e8 mice/group.
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ated. Rapamycin is remarkably effective in limiting pro-
gression in this construct, further highlighting the
translational potential of this therapeutic strategy.
MATERIALS AND METHODS
Animals
Male C57BL/6J mice aged 10e12 weeks were used for all
experiments. All animal protocols were in compliance with
the Laboratory Animal Care Guidelines of Stanford Univer-
sity, and reviewed and approved by the Stanford University
Administrative Panel on Laboratory Animal Care.
Aneurysm creation and follow-up
AAAs were created via intra-aortic PPE infusion as previ-
ously described.8,22 Brieﬂy, under inhaled anesthesia and
under operative magniﬁcation, 30 mL of type 1 PPE (1.5 U/
mL in saline, Catalog # 098K7008; Sigma-Aldrich, St. Louis,
MO, USA) was infused for 5 minutes into an isolated
segment of infrarenal aorta. At days 3, 7, and 14 after the
infusion procedure, the aortic diameter was measured
serially using the Vevo 770 ultrasound system (40 MHz
RMV-704 Scanhead with a resolution of 30 mm; Visual-
Sonics, Toronto, ON, Canada).8,22 Two investigators per-
formed all measurements independently, without
knowledge of study group assignment.
Rapamycin treatment
Rapamycin was purchased from the LC Laboratories
(Woburn, MA, USA) and prepared in 0.2% carboxy-methyl-
cellulose immediately prior to use. Mice were treated
daily with 5 mg/kg rapamycin or an equal volume of vehicle
alone via oral gavage, depending on study group assign-
ment, beginning 4 days after PPE infusion and continuing
for 10 days. This dose was chosen based on a literature
review of published work in atherosclerosis models.17e19
Histological analyses
Aortae were harvested 14 days after PPE infusion,
embedded in optimal cutting compound media, sectioned
(6 mm), and ﬁxed with cold acetone. Elastin integrity was
evaluated using Verhoeff’s Van Gieson (EVG) stain. SMCs,
macrophages, and angiogenesis were stained with anti-
bodies against SMC a actin, CD68, and CD31, respectively,
using a standard three-step biotinestreptavidineperoxidase
immunostain.8,22 Based on EVG and SMC a actin staining,
destruction of medial elastin and SMCs were graded as I
(mild) to IV (severe) if present:8,22 (I): elastin break/degra-
dation or SMC loss limited to one outer medial elastin layer;
(II): elastin degradation or SMC loss involving more than
two medial elastin layers, or entire medial elastin layers, but
limited to less than one-quarter of the aortic circumference;
(III): elastin degradation or SMC loss involving entire medial
elastin layers, but limited to less than half the aortic
circumference; and (IV): elastin degradation or SMC loss
involving entire medial elastin layers and expanded to morethan three-quarters of aortic circumference. Mural macro-
phages and angiogenesis were quantiﬁed as CD68þ cells
and CD31þ blood vessels, respectively, per aortic cross
section (ACS).
Statistical analysis
All data are presented as mean and standard deviation (SD),
and were analyzed using GraphPad Prism (version 5a;
GraphPad Software, La Jolla, CA, USA). Two-way ANOVA
(using the Bonferroni correction for multiple comparisons)
or the non-parametric ManneWhitney test was used to
identify differences between groups. Signiﬁcance was
assumed at p < .05.
RESULTS
Effects of rapamycin treatment on further progression of
established aneurysms
In our prior experience with this model, most mice develop
characteristic histological features and > 50.0% infrarenal
diameter enlargement consistent with AAA formation
within 3e4 days of PPE infusion.8 To evaluate the ability of
rapamycin to limit progression of established AAAs, mice
were treated with 5 mg/kg/d rapamycin via oral gavage,
beginning 4 days after the PPE infusion and continuing for
10 days in total. Prior to drug or vehicle treatment (3 days
after PPE infusion), ﬁve and six mice in the vehicle and
rapamycin groups, respectively, developed AAAs as deﬁned
by a > 50.0% increase in aortic diameters over the baseline
levels. As demonstrated in Fig. 1, rapamycin treatment was
associated with a small, but signiﬁcant, loss of weight
during the course of the experiment (103.8  4.9% and
97.2  3.6% of baseline levels in vehicle and rapamycin
groups, respectively; p < .05). Fig. 2 demonstrates the time-
dependent progression of aortic diameter, as determined by
ultrasound imaging. In vehicle-treated mice, aortic di-
ameters increased by an average of 0.13 and 0.36 mm
between days 3 and 10, respectively. In contrast, treatment
with rapamycin resulted in remarkable attenuation of
Figure 2. Effect of rapamycin treatment on aortic diameter. (A) Representative aortic ultrasound images prior to, and 10 days after, vehicle
or rapamycin treatment. (B) Serial measurements of aortic diameters in individual mice via ultrasound imaging following porcine
pancreatic elastase (PPE) infusion. (C) Mean and standard deviation of aortic diameters 3 and 10 days after treatment in individual groups.
Days 7 and 14 in (B) corresponded to days 3 and 10 in (C). ManneWhitney test, *p < .05 compared with vehicle group; n ¼ 7e8 mice/
group.
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0.17 mm for days 3 and 10, respectively, corresponding to a
38.0e53.0% reduction (p < .05 compared with vehicle
group). In this context, therefore, rapamycin treatment
appears effective in limiting further progression of estab-
lished experimental AAA.
Effects of rapamycin treatment on medial elastin and
SMCs
Medial elastin destruction and SMC depletion are hallmarks
of AAAhistopathology.To examine the inﬂuence of rapamycin
therapy on aortic structural integrity, EVG and SMC a-actin
staining was performed on aortic samples (Fig. 3). As indi-
cated by semi-quantitative analysis, rapamycin treatment
resulted in signiﬁcant aortic SMC retention compared with
vehicle treatment alone (p < .05). Further conﬁrmation was
obtained by counting SMC a-actin-positive cells in the aortic
media (56.3 8.4 and 32.7 16.2 cells/ACS in rapamycin and
vehicle-treated groups, respectively; p < 0.05). Although
some aortic elastin preservation was apparent in rapamycin-
treated mice, this difference was not signiﬁcant. These ﬁnd-
ings suggest a potential mechanism for rapamycin-induced
AAA suppression, speciﬁcally augmentation of aortic SMC
retention/preservation.
Effects of rapamycin treatment on mural macrophage
inﬁltration and angiogenesis
Macrophage accumulation and mural neoangiogenesis also
represent characteristic histopathologic features of
abdominal aortic degeneration. Mural macrophage density
and angiogenesis was examined in frozen aortic sections
using CD68 and CD31 monoclonal antibody immunostain-
ing, respectively. Numerous mural macrophages were pre-
sent in the aneurysmal aortae of vehicle-treated mice
(352  125 cells/ACS) (Fig. 4A, B). In rapamycin-treated
mice, macrophage density was reduced by 75.0%
(90  57 cells/ACS, p < .01). Similarly, adventitial CD31þ
neovessel density was signiﬁcantly lower (3  3 blood
vessels/ACS) than in vehicle-treated mice (19  12 blood
vessels/ACS), representing an 85.0% reduction (Fig. 4A, C)
(p < .01). These results suggest, in addition to effects onSMC preservation, that rapamycin therapy may limit aneu-
rysmal degeneration via suppression of mural macrophage
accumulation and adventitial neoangiogenesis.DISCUSSION
In this study, we found rapamycin to be remarkably effec-
tive in preventing the progression of established aneurysms.
Rapamycin-induced aneurysm inhibition was accompanied
by relative preservation in aortic architecture and reduced
inﬂammation. These results lend further support to existing
data supporting rapamycin as a prime translational candi-
date in early AAA disease suppression.20,21
Macrophages are likely the principal effector cells of
aneurysmal disease, contributing to aortic degradation via
the production of extracellular matrix-degrading pro-
teinases, lipid mediators, reactive oxygen species, and
proinﬂammatory cytokines.23e25 Aortic hemodynamic con-
ditions modulated aortic mural macrophage density and
aneurysm progression,26 as well as deﬁciency or inhibition
of the chemokine receptor CCR2 or its ligand CCL2.27e31
More recently, the cyclic peptide MKEY, an inhibitor of
CCL5eCXCL4 chemokine interaction, was also found to limit
experimental aneurysm progression while reducing mural
monocyte migration and macrophage density.8
The effect of rapamycin treatment on mural inﬂamma-
tion and aneurysm initiation/progression has been previ-
ously investigated to varying degrees. Prior experiments
have demonstrated the ability of rapamycin pretreatment
to subsequently suppress aneurysm progression following
subsequent AAA initiation, without apparently inﬂuencing
inﬂammatory cell inﬁltration.20 Discrepancy between those
ﬁndings and the results of the current study may be owing
to the ﬁvefold higher rapamycin dose employed in the latter
(although also administered by oral gavage).
Mural macrophage density is the summative end-organ
consequence of several related cellular processes, including
monocyte mobilization from systemic stores in the bone
marrow and spleen, transendothelial migration from the
bloodstream to inﬂamed aorta, and in situ macrophage pro-
liferation, retention, egress, and cell death.32,33 In patients
with chronic stable angina, the use of rapamycin-coated
Figure 3. Effects of rapamycin treatment on elastin and smooth muscle cell degradation. Aortic frozen sections prepared from mice 14 days
after porcine pancreatic elastase infusion were stained with Verhoeff’s Van Gieson or anti-smooth muscle cell (SMC) a actin antibody and
graded as I (mild) to IV (severe). (A) Representative staining images for medial elastin and SMCs. Scale bar ¼ 100 mm. (B, C) Mean and
standard deviation of the scores for SMC (B) and medial elastin (C) destruction. ManneWhitney test, *p < .05 compared with vehicle
group; n ¼ 7e8 mice/group.
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levels.34 Rapamycin down-regulated monocyte CCR2 and
CCR5 expression,35 and inhibited in vitromonocytemigration
towards CCL2 and other chemoattractants.36 Rapamycin also
inhibited vascular endothelial growth factor (VEGF)-A pro-
duction, another factor regulating inﬂuence on monocyte
migration.16,37,38 In congenitally hyperlipidemic mice, pre-
treatment with rapamycin was recently shown to reduce
aneurysm formation after exogenous angiotensin (Ang) II
infusion, in conjunction with a reduction in circulating
monocytes, and monocyte CCR2 expression.21 Thus, despite
earlier ﬁndings to the contrary, rapamycin may limit experi-
mental aneurysm initiation/progression through inﬂuences
on monocyte mobilization, migration, or tissue
differentiation.
In this study, rapamycin also reduced aortic mural
neovascularization in experimental AAAs. Although we
observed a trend that reduced aortic neovascularizationcorrelated with the attenuation of aortic enlargement to a
certain extent, it did not reach statistical signiﬁcance
(Spearman’s rank correlation ¼ 0.6, p > .05, data not
shown). While the signiﬁcance of this ﬁnding may have
been obscured by insufﬁcient power, given the number of
mice examined in this experiment, abundant prior ob-
servations link mural angiogenesis and AAA progres-
sion.37,39e43 Angiogenesis is tightly regulated by the
transcription factor, hypoxia inducible factor (HIF-1a). In
addition to hypoxia, growth factors, inﬂammatory cyto-
kines, and reactive oxygen species also modulate aortic
cellular expression of HIF-1a (and VEGF-A) in AAA dis-
ease.3,24,25,41,42,43e50 Because cellular levels vary, in part,
owing to mTOR-mediated signaling pathways,51 rapamy-
cin may attenuate AAA progression through inﬂuences on
HIF-1a-mediated aortic mural angiogenesis.
Several alternative immunosuppression reagents have
been shown to prevent experimental AAA formation, and
Figure 4. Effects of rapamycin treatment on mural angiogenesis and macrophage accumulation. Aortic frozen sections prepared from mice
14 days after porcine pancreatic elastase infusion were stained with monoclonal antibodies against CD31 and CD68. (A) Representative
immunostaining images for CD68þ macrophages and CD31þ blood vessels. Scale bar ¼ 100 mm. (B, C) Mean and standard deviation of
mural macrophages (B) and angiogenesis (C) quantiﬁed as CD68þ macrophages or CD31þ blood vessels per aortic cross section (ACS).
ManneWhitney test, **p < .01 compared with vehicle group; n ¼ 7e8 mice/group.
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gression of established AAAs.4,5,52,53 Interestingly, however,
in patients receiving these drugs for long-term immuno-
suppression, existing AAA growth has been unaffected or
even accelerated.54,55 Rapamycin may fare differently in this
regard. For example, in addition to its inﬂuences on aortic
mural macrophage density and neoangiogenesis, rapamycin
inhibits T cell production of interferon-g and interleukin-17,
important mediators of AAA progression,23,56 and induces
regulatory T cells, a negative regulator for aneurysm dis-
ease.57,58 Rapamycin also diminishes classically activated
macrophage polarization in experimental aneurysm
models.21
Finally, we and others have demonstrated the critical role
of Ang II receptor in AAA pathogenesis, even in models
created without exogenous Ang II administration.22,59
Among many other pro-aneurysmal inﬂuences on theaorta, Ang II also activates the mTOR pathway in vascular
constitutive cells.60,61 Thus many properties of rapamycin,
apart from its known inﬂuences on immunological compe-
tence, may account for its effectiveness in experimental
(and potentially clinical) AAA suppression.
Because the primary goal of these experiments was to
examine the inﬂuence of rapamycin on the progression of
established AAAs, some limitations exist regarding the
generalizeability of these results. As has been reported
previously in the experimental literature, the dose of
rapamycin employed (5 mg/kg/day) was far higher than the
standard human clinical dose (up to 40 mg daily [<1 mg/
kg/day], and more typically 2e5 mg daily for maintenance
dosing) (USPI guide for oral rapamune/sirolimus therapy;
Pﬁzer, Philadelphia, PA, USA). The question of whether
rapamycin, in the clinical dosing range, is effective at
limiting experimental AAA progression was not speciﬁcally
498 M. Rouer et al.addressed in this study. Similarly, a dose-ranging experi-
ment was also outside the scope of this investigation. Given
its long half-time (approximately 60 hours), a reduced fre-
quency of administration may also maintain efﬁcacy at
lower total doses. Thus, substantial work will be required
before clinical trials can be justiﬁed in patients with early
AAA disease.
Evaluation of the therapeutic efﬁcacy of rapamycin was
limited to transabdominal ultrasonography in vivo and aortic
histological analyses. Further exploration of the cellular and
molecular mechanisms responsible for the suppression of
AAA progression by rapamycin are beyond the scope of this
evaluation. Effects on aortic mural SMC preservation may be
attributed to direct or indirect inﬂuences on apoptosis,
survival, proliferation, and/or other regenerating properties
of SMCs. Additionally, 10-day rapamycin treatment led to <
10.0% reduction body weight gain compared with vehicle
treatment. Given the importance of body weight/mass on
aneurysm growth, we cannot exclude the possibility that
small reduced body weight gain by rapamycin may, in part,
inﬂuence AAA growth.
CONCLUSION
Rapamycin limits progression of established experimental
aneurysms, further supporting its translation potential in
human AAA disease management.
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